Clinical Trials Logo

Acute Lymphoid Leukemia clinical trials

View clinical trials related to Acute Lymphoid Leukemia.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02435550 Terminated - Multiple Myeloma Clinical Trials

iCare for Cancer Patients

Start date: June 26, 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to use genomic information from individual patients to create simulation avatars that will be used to predict novel drug combinations with therapeutic potential.

NCT ID: NCT02419755 Terminated - Clinical trials for Acute Myeloid Leukemia

Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

Start date: April 14, 2015
Phase: Phase 2
Study type: Interventional

This study will test the safety and effectiveness of adding bortezomib and vorinostat to other chemotherapy drugs commonly used to treat relapsed or refractory leukemia. Both drugs have been approved by the Food and Drug Administration (FDA) to treat other cancers in adults, but they have not yet been approved tor treatment younger patients with leukemia. PRIMARY OBJECTIVE - To estimate the overall response rate of patients with MLL rearranged (MLLr) hematologic malignancies receiving bortezomib and vorinostat in combination with a chemotherapy backbone. SECONDARY OBJECTIVES - Estimate event-free and overall-survival. - Describe toxicities experienced by participants during treatment. OTHER PRESPECIFIED OBJECTIVES - To identify all genomic lesions by comprehensive whole genome, exome and transcriptome sequencing on all patients. - To compare minimal residual disease (MRD) results by three modalities: flow cytometry, polymerase chain reaction (PCR) and deep sequencing.

NCT ID: NCT01749111 Terminated - Clinical trials for Myelodysplastic Syndrome

Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis

CICLODECH
Start date: December 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether cyclophosphamide post bone marrow transplant increases the rate of patients alive, in remission and without immunosuppression, one year after transplant, when compared with the combination of methotrexate and calcineurin inhibitor

NCT ID: NCT01037764 Terminated - Clinical trials for Acute Lymphoid Leukemia

Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)

AHCTALL
Start date: January 2010
Phase: Phase 2
Study type: Interventional

[Study Objectives] - To evaluate the efficacy of allogeneic hematopoietic cell transplantation (HCT) in patients with acute lymphoblastic leukemia (ALL) in the first or second complete remission (CR). The efficacy of the treatment will be measured in terms of the frequency of relapse and duration of remission (the primary endpoints). - The secondary end points of the study include; engraftment, donor chimerism, secondary graft failure, acute and chronic graft-versus-host disease (GVHD), immune recovery, infections, transplantation-related mortality, leukemia free survival, and overall survival.